Literature DB >> 10908286

Oncostatin M is produced during pregnancy by decidual cells and stimulates the release of HCG.

I Ogata1, K Shimoya, A Moriyama, Y Shiki, Y Matsumura, K Yamanaka, T Nobunaga, Y Tokugawa, T Kimura, M Koyama, C Azuma, Y Murata.   

Abstract

Oncostatin M (OSM) is a member of the interleukin-6 superfamily and a multifunctional cytokine that effects the growth and differentiation of many different cell types. OSM concentrations in the sera of pregnant women were found to be significantly higher than those of non-pregnant women. Western blot analysis revealed that the OSM protein was present in the decidua and chorionic tissue in each trimester. Throughout pregnancy, the amount of the OSM protein in the decidua was larger than that in the chorionic tissue. Immunohistochemistry using an anti-OSM monoclonal antibody demonstrated that OSM was mainly localized in the decidual glands and stroma. OSM transcripts in the decidua and the chorionic tissue were detected during each trimester by reverse transcription-polymerase chain reaction (RT-PCR). The regulation of human chorionic gonadotrophin (HCG) release by the placenta in first trimester stimulated with recombinant OSM was also investigated. Stimulation of the placenta by OSM augmented HCG release in a time- and dose-dependent manner. HCG release induced by recombinant human OSM was completely blocked by antibodies against OSM and the signal transducer, gp130, but only partially inhibited by antibodies against the leukaemia inhibiting factor (LIF) receptor. These results suggest that OSM molecules produced by decidual glands and stromal cells during pregnancy have an important role in placental endocrine function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908286     DOI: 10.1093/molehr/6.8.750

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  6 in total

1.  IL-6 trans-signaling system in intra-amniotic inflammation, preterm birth, and preterm premature rupture of the membranes.

Authors:  Sarah Y Lee; Irina A Buhimschi; Antonette T Dulay; Unzila A Ali; Guomao Zhao; Sonya S Abdel-Razeq; Mert O Bahtiyar; Stephen F Thung; Edmund F Funai; Catalin S Buhimschi
Journal:  J Immunol       Date:  2011-01-31       Impact factor: 5.422

Review 2.  Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects.

Authors:  P Fischer; D Hilfiker-Kleiner
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

3.  Effects of Oncostatin M on Invasion of Primary Trophoblasts under Normoxia and Hypoxia Conditions.

Authors:  Jeong Ha Wie; Hyun Sun Ko; Sae Kyung Choi; In Yang Park; Ahyoung Kim; Ho Shik Kim; Jong Chul Shin
Journal:  Yonsei Med J       Date:  2018-09       Impact factor: 2.759

4.  Examination of the Myokine Response in Pregnant and Non-pregnant Women Following an Acute Bout of Moderate-Intensity Walking.

Authors:  Kelly Ann Hutchinson; Shuhiba Mohammad; Léa Garneau; Kurt McInnis; Céline Aguer; Kristi B Adamo
Journal:  Front Physiol       Date:  2019-10-10       Impact factor: 4.566

5.  Oncostatin M stimulates cell migration and proliferation by down-regulating E-cadherin in HTR8/SVneo cell line through STAT3 activation.

Authors:  Hyun Sun Ko; Sae Kyung Choi; Hee Kyung Kang; Ho Shik Kim; Ji Hyun Jeon; In Yang Park; Jong Chul Shin
Journal:  Reprod Biol Endocrinol       Date:  2013-09-24       Impact factor: 5.211

6.  STAT3 and ERK Signaling Pathways Are Implicated in the Invasion Activity by Oncostatin M through Induction of Matrix Metalloproteinases 2 and 9.

Authors:  Hyun Sun Ko; Byung Joon Park; Sae Kyung Choi; Hee Kyung Kang; Ahyoung Kim; Ho Shik Kim; In Yang Park; Jong Chul Shin
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.